Trial | NCT02406989  Report issue

Title

A Multiple-Ascending Dose Study of MS-553 in Healthy Volunteers
A Randomized, Double-Blind, Placebo-Controlled, Phase 1, Multiple-Ascending Dose Study of MS-553 in Healthy Volunteers

  • Phase

    Phase 1

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    ms-553 ...

  • Study Participants

    32
This is a randomized, double-blind, placebo-controlled, multiple-ascending dose study of MS-553 in healthy volunteers. Endpoints are safety, tolerability, and pharmacokinetics. Subjects are dosed for 14 days.
Study Started
Apr 30
2015
Primary Completion
Aug 31
2015
Study Completion
Sep 30
2015
Last Update
Mar 16
2016
Estimate

Drug MS-553

Study Drug

Drug Placebo

Matching placebo to MS-553

Placebo Placebo Comparator

Placebo oral tablet BID x 14 days

MS-553 Experimental

MS-553 oral tablet BID x 14 days

Criteria 

Inclusion Criteria:

In good general health with BMI 18 to 32 kg/m2. Females must be nonpregnant, nonlactating, postmenopausal at least 2 years or surgically sterilized at least 6 months prior

Exclusion Criteria:

History of skin rash, migraine, or clinically significant ocular diseases, conditions predisposing to QT prolongation
No Results Posted